Cleveland BioLabs (CBLI), Panacela Labs Receive $4.6M Contract in Russia for Xenomycins Development
Cleveland BioLabs, Inc. (Nasdaq: CBLI) and Panacela Labs, Inc. announced award of a contract valued at 146 million rubles, or approximately $4.6 million (based on current exchange rates), with the Ministry of Industry and Trade of the Russian Federation for development of Xenomycins, a family of compounds in development as anti-infective agents. The contract, issued under the Russian Federation's "Pharma 2020" development initiative, provides matching funding over a period of approximately three years, which will be used to support preclinical and clinical studies.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OPKO Health's (OPK) NDA for Rayaldee Accepted by FDA
- Steel Gains as Cold-Rolled Trade Case Filed; Hot-Rolled, Stainless Steel Cases Seen as Likely, Says Analyst (AKS) (X) (NUE) (MT) (STLD)
- Loxo Oncology (LOXO), University of Colorado Cancer Center Announce Publication of LOXO-101 Phase 1 Data in TRK
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!